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Abstract: Fat mass (FM) gain and lean mass (LM) loss are common side effects for patients with
prostate cancer receiving androgen deprivation therapy (ADT). Excess FM has been associated
with an increased risk of developing obesity-related comorbidities, exacerbating prostate cancer
progression, and all-cause and cancer-specific mortality. LM is the predominant contributor to resting
metabolic rate, with any loss impacting long-term weight management as well as physical function.
Therefore, reducing FM and preserving LM may improve patient-reported outcomes, risk of disease
progression, and ameliorate comorbidity development. In ADT-treated patients, exercise and nutri-
tion programs can lead to improvements in quality of life and physical function; however, effects on
body composition have been variable. The aim of this review was to provide a descriptive overview
and critical appraisal of exercise and nutrition-based interventions in prostate cancer patients on
ADT and their effect on FM and LM. Our findings are that FM gain and LM loss are side effects of
ADT that could be reduced, prevented, or even reversed with the implementation of a combined
exercise and nutrition program. However, the most effective combination of specific exercise and
nutrition prescriptions are yet to be determined, and thus should be a focus for future studies.
Keywords: androgen deprivation therapy; prostate cancer; exercise; nutrition; fat mass; lean mass
1. Introduction
Androgen deprivation therapy (ADT) is a mainstay treatment for prostate cancer
(PCa), where more than half of patients will receive ADT at some point during their can-
cer journey [1]. ADT is a pharmaceutical or surgical strategy that deprives the body of
androgens, thereby slowing cancer growth [2]. This may be achieved by either reduc-
ing testosterone concentrations to castrate levels defined as <50 ng/dL (<1.7 nmol/L)
using luteinizing hormone-releasing hormone agonists, antagonists or an orchiectomy
procedure, or by blocking the androgen receptors to eliminate testosterone binding using
anti-androgens [2]. Given that testosterone plays roles in the activation of lipolysis and
hypertrophy of lean mass (LM) [3,4], substantial body composition changes, as well as
loss of muscle strength and physical function, can occur [5,6]. Within the first 9 months
of treatment initiation, patients have been reported to experience a 13.8% increase in fat
Nutrients 2021, 13, 1664. https://doi.org/10.3390/nu13051664 https://www.mdpi.com/journal/nutrients
Nutrients 2021, 13, 1664 2 of 18
mass (FM) and a 2.4% decrease in LM [5]. This change in body composition places patients
with PCa at increased risk of obesity-related comorbidities, treatment-related side effects,
development of a more aggressive cancer, and PCa-specific mortality [7–10].
Excess FM upregulates pro-inflammatory cytokines, leading to a state of low-grade
chronic inflammation, which is associated with decreased cancer cell apoptosis, increased
cancer cell growth, angiogenesis, and metastases, and increased risk of developing car-
diovascular disease and type 2 diabetes (Figure 1) [7,11,12]. Post-diagnosis obese prostate
cancer patients with non-metastatic disease are more likely to experience cardiovascular
disease-related mortality than non-obese patients (hazard ratio of 1.24) [13]. In addition,
PCa patients on ADT with greater FM may experience higher fatigue, lower vitality, and
higher blood triglyceride concentrations [14,15]. A loss of LM also contributes to poorer
patient outcomes [14]. The development of sarcopenic obesity, a progressive loss of LM and
gain in FM, has been associated with multiple physical disabilities (Figure 1) [16,17]. Lean
mass is also the predominant contributor to resting metabolic rate. Therefore, preserving
or increasing LM is important for long-term weight loss maintenance [18]. Promoting
LM gain can also increase glucose storage, facilitate glucose clearance from circulation,
and reduce the amount of insulin required to maintain normal glucose tolerance [19],
which is important as insulin resistance may exacerbate cancer progression [20]. Owing
to the association between FM gain or LM loss and worse patient outcomes, strategies to
prevent or reverse this process are important to include as adjuvant therapies while on
ADT, particularly for those who are obese [9].
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Exercise and nutrition interventions are effective strategies to reduce FM and in-
crease LM in non-cancer populations [21]. Researchers conducting clinical studies in the 
PCa population have reported that exercise interventions result in improved quality of 
life and reduced ADT-related side effects such as cancer-related fatigue and poorer phys-
ical function [22]. Nutrition interventions have been demonstrated to induce weight loss, 
improve bone health, and in some instances slow PCa progression, although evidence is 
limited [23–25]. Despite these beneficial outcomes, the variety of intervention designs, 
c cer patients receiving ADT can develop sarcopenic obesity due to a treatment-induced increas in fat
mass and decr ase in lean mass. Thes respective body composition changes can lead to poor patient o tc s. I
created ith BioRender.co (accessed on 20 November 2020).
nutrition interventions are eff ctive stra egi s to reduce FM and increase
LM in non-ca cer populations [21]. Research rs conducting cli ical studies in the PCa
population have repo ted that exercis int rventio s result in improved quality of life
and reduced ADT-relat d si e effects such as cancer-related fatigue and poorer physical
function [22]. Nutri ion i terventions have be n demonstrated to in ce ,
i l , i i l i , l i i
li it [ 25]. Despite these beneficial outcomes, the variety of intervention designs, aims,
cohorts, and outcomes, presents variable evidence as to whether exercise and nutrition
interventions have a desirable effect on FM and LM for patients undergoing ADT. When
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examining body composition in ADT-treated patients, exercise has been the preferential
intervention utilised. As such, there is a lack of clarity concerning the feasibility and
efficacy of combined exercise and nutrition programs and the effect on FM loss, while
simultaneously seeking to preserve or enhance LM. Therefore, this review is a descriptive
overview and critical appraisal of exercise and nutrition-based interventions in ADT-
treated PCa patients and the effect on FM and LM, and to propose possible avenues for
further research.
MEDLINE and Scopus databases were searched with published studies included
until November 2020. Search terms included various combinations of: prostate cancer;
androgen deprivation therapy; exercise; nutrition; body composition; fat mass; lean mass.
Secondary searches involved reference lists of eligible articles as well as systematic reviews
and meta-analyses assessing interventions given to patients on ADT. The key criterion
was to identify studies that included PCa patients receiving ADT at time of intervention,
utilising an exercise, nutrition or combined intervention, while including a measure of FM
and/or LM.
2. Using Exercise to Decrease Fat Mass and Preserve or Gain Lean Mass
2.1. Aerobic Exercise
Aerobic exercise is an ideal intervention for FM loss as it is familiar to non-exercisers,
e.g., walking, easy to implement at home with little to no equipment, promotes higher
utilisation of lipids, and includes modes allowing reduced impact on joints, e.g., swim-
ming [26,27]. The aerobic exercise guidelines for prostate cancer patients recommended
within clinical practice suggest an accumulation of 150 min/week of moderate-to-vigorous
intensity or 300 min/week if weight loss is intended (Table 1) [28]. In this section, we
evaluate six studies examining aerobic-based interventions and the effect on FM and LM.
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Aerobic training
150 min/week of moderate
intensity exercise or
75 min/week of vigorous
intensity exercise
300 min/week of moderate
intensity exercis or
150 min/week of vigorous
intensity exercise
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tritio al intake
Healthy balanced diet with
high fruit and vegetables, low
saturated fats, and adequate
calcium (<1200 mg/d) and
vitamin D (>600 IU)
2100–4200 kJ daily
energy deficit
Images created with BioRender.com (accessed on 5 April 2021).
Hvid et al. [29] compared he lthy aged-matched cont ols with normal testosterone
concentrations (10–28 nmol/L), and ADT-treated PCa patients with castrate levels of
testosterone (<1.7 nmol/L) completing the same 12 week aerobic-based cycling intervention
utilising high-intensity interval training (Table 2). Both groups significantly lost whole-
body, trunk, visceral, and subcutaneous FM, while preserving LM, with no between-group
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differences. The castrate levels of testosterone in ADT-treated patients, therefore, does
not appear to inhibit FM loss via high-intensity aerobic exercise. However, the healthy
controls exhibited a superior loss of intermuscular FM (−8.5% vs. 0%). The presence of
substantial intermuscular FM could interfere with muscle fibre quality and contribute to
insulin resistance, reduction in muscle strength, and increased fatigue [27,30,31], although
there was no between-group difference for insulin sensitivity; muscle strength and fatigue
were not measured. However, this study contained a small sample size and did not include
a PCa control group. Therefore, it is unclear whether the intervention prevented further
ADT-induced increases in intermuscular FM and if this in turn affects muscle fibre quality.
Furthermore, the groups had baseline cardiorespiratory fitness levels of 27.2 mL/kg/min
and 25.2 mL/kg/min, respectively, and prostate cancer patients staged T1 a/b to T3 a/b.
Therefore, the use of high-intensity aerobic-based exercise is uncertain for patients with
poor cardiorespiratory fitness or more advanced disease.


























at 60–70% 1 RM
DXA
Aerobic (N = 40)
ADT BF% 31.2% 33.3% *
Lean mass 65.0 63.0 *
No ADT BF% 29.9% 30.5%
Lean mass 66.2 65.7
Resistance (N = 40)
ADT BF% 32.6% 33.0% §UC
Lean mass 63.7 63.4 §UC
No ADT BF% 29.7% 29.2%
Lean mass 66.7 67.3
Usual care (N = 41)
ADT BF% 32.0% 35.2% §R *
Lean mass 64.2 61.1 §R *
No ADT BF% 31.2 30.6

















exercise (N = 9)
Fat mass 24.4 23.1 #
Trunk fat 14.5 13.4 #
Lean mass 52.3 52.3
BF% 31.1% 29.8% #
Visceral a −8.4% #
Subcutaneous a −4.9% #




Fat mass 20.5 19.6 #
Trunk fat 12.4 11.8 #
Lean mass 56.3 56.2
BF% 25.7% 25.0% #
Visceral a −5.8% #
Subcutaneous a −2.5% #
Intermuscular a −8.5% #
Santa Mina












Aerobic (N = 22) Chest skinfold 35.6 mm 33.5 mm *3
BF% 28.5% 27.3% *3
Resistance (N = 34) Chest skinfold 35.3 mm 33.7 mm
BF% 28.0% 27.3%
Santa Mina
et al. [34] RCT
Blood
biomarkers
See Santa Mina et al. [33] Skinfolds
Aerobic (N = 13) BF% 28.4% 26.4%
Resistance (N = 13) BF% 26.5% 25.3%
Uth et al.
[35] RCT Lean mass
12 weeks
2 ×/week (1–8 weeks)




Football (N= 29) Fat mass 27.6 26.3
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BF% 32.6% 31.7%
Usual care (N = 28) Fat mass 30.0 29.7
Lean mass 56.7 56.8
BF% 32.9% 32.9%
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Fat mass 24.0 25.1
Lean mass 57.9 59.3
ASM 25.0 25.9 §6DEL
Aerobic/resistance
(N = 50)
Fat mass 22.8 23.7
Lean mass 58.1 58.7
ASM 25.2 25.6
Delay/aerobic
(N = 47) Fat mass 27.1 28.3













6–12 RM, 2–4 sets
DXA
Resistance (N = 10) Fat mass 25.7 24.9
Lean mass 52.2 52.0
BF% 30.7% 30.6%
Quadriceps
thickness 2.15 cm 2.46 cm *
Hamstring
thickness 4.52 cm 1.53 cm
Biceps
thickness 2.69 cm 2.91 cm
Triceps
thickness 1.94 cm 2.33 cm
Alberga
et al. [32] Details in aerobic section
Santa Mina
et al. [33] Details in aerobic section
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repetitions, first 5 at 5 RM
DXA and CT
Resistance (N = 17) Fat mass 31.2 31.1
Subcutaneous 118 cm2 118 cm2
Intermuscular 7.9 cm2 7.6 cm2
Lean mass 62.4 64.1 *
BF% 31.4% 30.7% *
Nilsen et al.




6–10 RM, 1–3 sets
DXA
Resistance (N = 28) Fat mass 26.5 26.4
Trunk fat 14.7 14.6
Lean mass 59.8 60.3
ASM 25.2 25.7 §
BF% 29.5% 29.3%
Control (N = 30) Fat mass 26.4 26.7
Trunk fat 14.6 14.7
Lean mass 57.9 57.9
ASM 24.8 24.7
BF% 30.0% 30.2%

















[40] RCT Lean mass
12 weeks
2 ×/week
Supervised aerobic at 65–80%
HRmax
Resistance exercise 6–12 RM,
2–4 sets
DXA
Exercise (N = 29) Fat mass 22.5 22.3
Trunk fat 12.2 11.9
Lean mass 56.1 56.8 §
ASM 23.5 24.0 §
BF% 27.5% 27.2%
Usual care (N = 28) Fat mass 23.2 23.5
Trunk fat 12.4 12.2







See Galvão et al. [40] DXA
Acute ADT (N = 16) Fat mass 22.7 23.3 § *
Trunk fat 12.2 12.4
Lean mass 58.5 59.1
ASM 24.7 25.2
BF% 26.8% 27.2% §
Chronic ADT
(N = 34) b
Fat mass 23.4 23.0 *
Trunk fat 12.1 11.8 *
Lean mass 56.5 57.4 *
ASM 23.8 24.4 *
BF% 28.1% 27.4% *
Cormie et al.




Supervised aerobic at 70–85%
HRmax
Resistance exercise at 60–85%
1 RM
Home-based exercise of choice
DXA
Exercise (N = 32) Fat mass 26.9 26.3 §
Trunk fat 14.8 14.3 §
Visceral fat 913 g 874 g *
Lean mass 56.6 56.0
ASM 23.7 23.5 §
BF% 30.6% 30.5% §
Usual care (N = 31) Fat mass 26.9 27.8 *
Trunk fat 15.2 15.5
Visceral fat 926 g 922 g
Lean mass 58.7 57.3 *
ASM 24.9 24.3 *














Home-based exercise of choice
DXA
Exercise (N = 29) Fat mass 24.3 23.9 §
Trunk fat 13.5 13.1
Lean mass 59.2 59.2
BF% 28.7% 28.4%
Flexibility (N = 22) Fat mass 28.4 29.9
Trunk fat 15.0 15.4









Supervised aerobic at 70–90%
HRmax





Exercise (N = 50) Fat mass 24.1 24.5 §
Trunk fat 13.2 13.0 §
Lean mass 59.4 60.1 §
BF% 27.2% 27.2% §
Usual care (N = 47) Fat mass 25.7 27.2
Trunk fat 14.2 14.9
Lean mass 58.7 58.6
BF% 28.2% 30.3%
Newton
et al. [36] Details in aerobic section
Ndjavera
et al. [44] RCT Fat mass
12 weeks
2 ×/week
Supervised aerobic at 55–85%
HRmax




Exercise (N = 24) Fat mass 24.3 21.7
Fat-free mass 58.2 58.9
Usual care (N = 26) Fat mass 23.3 22.7
Fat-free mass 59.1 58.2
* = Significant within group change; § = significant between-group change; §UC = significant between-group change with usual care
control group; §R = significant between-group change with resistance training group; # = effect of time in the two groups pooled together;
§6DEL = significantly different to delayed/aerobic group at 6 months only, not 12 months which is the value reported in the table;
*3 = significant loss at 3 months only, but not 6 months which is the value reported in the table. a Only reported mean change; b Acute
ADT < 6 months, chronic ADT ≥ 6 months. RCT = randomised controlled trial; ×/week = times per week; HRmax = maximum heart
rate; RM = repetition maximum; DXA = dual x-ray absorptiometry; ADT = androgen deprivation therapy; BF% = body fat percent;
VO2max = oxygen consumption; MRI = magnetic resonance imaging; RPE = rate of perceived exertion; CT = computed tomography;
ASM = appendicular skeletal muscle; BIA = bioimpedance analysis.
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Uth et al. [35] utilised an unstructured form of interval-based aerobic training, in the
form of football (soccer) game play and skill development (Table 2). Unlike Hvid et al. [29],
they recruited patients with bone metastases (19.3%), but similarly assessed an apparently
healthy prostate cancer cohort with only 5.3% of patients self-reporting a sedentary lifestyle,
with baseline cardiorespiratory fitness of 27.2 and 26.4 mL/kg/min, and mean body mass
index of 26.7 and 27.6 kg/m2, respectively. They reported a mean 0.5 kg significant increase
in LM and a mean 0.6 kg loss of FM that approached within-group significance. With the
improvement in LM and a trend for an effect on FM, sport-orientated activities may be an
effective alternative to clinic-based interventions in ameliorating treatment-related body
composition changes. Several adverse events were reported in the football group including
fracture, tendon tear, and sprain. While no injury was related to bone metastases and
most participants recovered and continued with the study, there is uncertainty whether
such an intervention would be feasible for high-risk patients, e.g., obese patients with
multiple comorbidities. Injury risk is higher within a team sport environment, compared to
individual sport or exercise, due to the unpredictable nature of opponents, teammates, and
ball. The authors suggested a lead-in period may be required to improve strength, balance,
and ball handling to reduce injury risks [35].
In contrast to the previous studies using interval training [29,35], Newton et al. [36]
and Alberga et al. [32] utilised clinic-based continuous aerobic exercise (Table 2). Examining
a cohort that excluded patients with bone metastases, Newton et al. [36] used a three-arm
study design over 12 months comparing impact and resistance exercise, aerobic and
resistance exercise, and delayed aerobic exercise after 6 months of usual care. When
compared to the aerobic-only exercise group during the 6–12 month period, no differences
in FM or LM were noted between groups. Alberga et al. [32] also utilised a three-arm study
design comparing aerobic exercise, resistance exercise, and usual care across a 24-week
period, in ADT and non-ADT groups, although the two treatment types were not compared.
The ADT aerobic group exhibited an undesirable significant increase in body fat percentage
(BF%) and 2 kg reduction in LM, although not statistically different to the other ADT
groups. The researchers did not report FM, so it is unclear whether a change in FM, in
addition to the LM loss, contributed to the modification in BF%. The decline in LM is
substantial and concerning, suggesting the prescribed aerobic exercise was insufficient to
prevent ADT-related declines in LM, in contrast to a non-significant 0.5 kg loss in LM in
the non-ADT aerobic group.
The previously described studies were supervised interventions [29,32,35,36]. How-
ever, ongoing supervision is not always viable. Santa Mina et al. [33,34] compared home-
based aerobic and resistance exercise over 6 months examining patients with non-metastatic
disease. Santa Mina et al. [34] used a smaller non-randomised group of the same cohort to
report on blood biomarkers (Table 2). There were significant within-group declines in chest
skinfold thickness and BF% at 3 months, but not 6 months [33] and weight change was
positively associated with changes in leptin and the leptin:adiponectin ratio, and negatively
associated with IGF-1:IGFBP-3 ratio [34], which are proposed markers associated with PCa
progression [45]. Although the use of anthropometric measures suggest weight loss may
improve risk of cancer progression, the researchers could not confirm if these changes were
subject to alterations in FM or LM. Nonetheless, both studies provide valuable insight
into the potential of home-based programs, although there is still uncertainty if those with
metastatic disease would benefit from a similar program.
2.2. Resistance Exercise
Weight loss can occur through loss of both fat and muscle tissue [46]; however, sub-
stantial loss of LM may exacerbate sarcopenia, reduce physical function, and increase
risk of falls [47]. Resistance exercise is commonly prescribed for muscle hypertrophy [48].
Within clinical practice prostate cancer patients are recommended to complete resistance
training on a minimum of two days each week (Table 1) [28]. This section is an evaluation
of six studies examining resistance exercise and the effect on FM and LM.
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Galvão et al. [37] and Hanson et al. [38] conducted single-group studies and both ex-
cluded patients with metastatic disease (Table 2). Galvão et al. [37] prescribed a traditional
periodised resistance training program over 20 weeks and found no change in FM or LM
except for a significant increase in quadriceps thickness. In contrast, Hanson et al. [38]
utilised drop sets and repetitions to failure over a 12-week program. The exercise set began
at five repetition maximum and once volitional fatigue was reached the resistance was
reduced until 15 repetitions were achieved. A significant decrease in BF% and increase in
LM were reported. The differing results may be explained by the period between the two
studies and cohort examined. At the time of the Galvão et al. [37] study, the use of resis-
tance training for PCa patients was somewhat revolutionary and a conservative exercise
prescription was implemented with only 10 patients recruited. The Hanson et al. [38] study
was completed over a decade later in a cohort of 17 patients of African American ethnicity
with higher intensity and sophistication of resistance training design. While these studies
demonstrate the feasibility of resistance training in promoting changes to LM, both studies
utilised small or non-diverse cohorts, so the generalisability of these results is unclear.
Nilsen et al. [39] examined a 16-week clinic-based high-load periodised resistance
training program in which the intervention group significantly improved appendicular
skeletal muscle (ASM). However, no changes were found for whole-body LM or FM or for
any body composition measure when compared to the usual care controls (Table 2). High-
risk patients with medical conditions that could complicate participation were excluded
from this study, although cancer stage of included patients was not reported. Nevertheless,
three patients withdrew from the intervention group due to pain. Further research is
required into the appropriateness of high-load resistance training for high-risk patients
and may require a gradual increase in intensity. Furthermore, while the recruitment goal
was met in this study, the authors reported to be uncertain whether the effect size selected
to calculate sample size was appropriate to detect a change in LM.
Resistance and aerobic exercise are both recommended in the PCa survivorship guide-
lines [28]. Therefore, it is important to understand how patients respond to each exercise
mode. Alberga et al. [32] and Santa Mina et al. [33,34] compared aerobic and resistance
exercise (Table 2). Alberga et al. [32] utilised clinic-based periodised resistance training
conducted over 24 weeks and reported preservation of BF% and LM, which was signifi-
cantly different to usual care controls who gained BF% and lost LM. The 2 kg LM loss in the
aerobic group although not statistically different to the 0.3 kg loss in the resistance group,
is of clinical relevance and highlights the importance of resistance training in preserving
LM. Santa Mina et al. [33,34] examined home-based resistance exercise utilising bands,
balls, and body weight exercises, and reported no training effect [33,34]. From this work, it
appears that resistance training alone is insufficient to induce FM loss. However, it may
prevent further ADT-induced body composition changes and specifically alleviate loss
of LM.
2.3. Multi-Modal Interventions
The inclusion of multiple exercise modes is important when the intention is to al-
ter both FM and LM. In this section, we evaluate seven studies utilising multi-modal
interventions and the effect on FM and LM.
Several authors examined similar cohorts without bone metastases and compared
combined aerobic and resistance exercise interventions to usual care controls (Table 2).
Galvão et al. [40] reported significant between-group differences in whole-body LM and
ASM, but no change in FM over 12 weeks. Cormie et al. [41] found significant between-
group differences for whole-body and trunk FM, BF%, and ASM over the 12-week interven-
tion. The intervention group demonstrated a significant within-group loss of visceral FM,
while the control group significantly lost LM, ASM, and gained whole-body FM and BF%.
Wall et al. [43] reported significant between-group differences for whole-body FM and LM,
trunk FM, and BF% but conducted a longer intervention of six months. Ndjavera et al. [44]
reported no body composition changes over their 12-week intervention. Cormie et al. [41],
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Wall et al. [43], and Ndjavera et al. [44] reported greater adjusted group mean differences
for FM (−1.4, −1.1, and −1.9 kg, respectively) than Galvão et al. [40] (−0.01 kg), which
could be explained by the larger volume of aerobic exercise prescribed in these studies.
Galvão et al. [15] was a secondary analysis of the previously described Galvão et al. [40]
study and they compared different durations of ADT: chronic ≥ 6 months, and acute
< 6 months, completing the same intervention (Table 2). The authors reported a significant
between-group difference in FM with those on chronic ADT experiencing a 0.4 kg loss
compared to a 0.6 kg gain in the acute ADT group over 12 weeks. Furthermore, triglyceride
concentrations were significantly different between groups, which was associated with
the observed changes in FM. Despite these significant findings it resulted in an uneven
distribution between acute (n = 16) and chronic (n = 34) ADT-treated patients due to the
use of a delayed exercise control group. The smaller number in the acute group may have
limited the ability to observe differences between groups. Regardless, it is important to
note that body composition declines are greater during the initial 3–6 months of ADT
commencement and appear more difficult to ameliorate with exercise therapy.
Aerobic and resistance-based exercise are the most commonly prescribed modes;
however, both Newton et al. [36] and Winters-Stone et al. [42] examined the combined
effect of impact training, e.g., bounding movements, and resistance training (Table 2).
Newton et al. [36] reported that the combined impact/resistance group significantly im-
proved ASM compared to the usual care controls at 6 months. However, no effect on ASM
was noted after the same resistance training was undertaken by the aerobic/resistance
group. The authors described a potential interference effect when combining aerobic and
resistance training within the same session, which may have compromised muscle hyper-
trophy [49]. Winters-Stone et al. [42] reported that FM was significantly decreased in the
impact/resistance group compared to a flexibility control group who continued to gain FM.
Additionally, in line with the Santa Mina et al. [34] findings, Winters-Stone et al. [42] re-
ported that the changes in FM mediated differences in insulin, suggesting FM loss induced
an insulin-lowering effect.
3. Using Nutrition to Decrease Fat Mass and Preserve or Gain Lean Mass
3.1. Healthy Eating Guidelines and/or Energy Deficit
Healthy eating guidelines are recommended portions of each food group to be con-
sumed daily [50]. Weight loss in its simplest form is achieved through greater energy
expenditure over intake creating a daily energy deficit (Figure 2) [51]. Clinical practice
guidelines recommend prostate cancer patients to consume a healthy balanced diet high
in fruit and vegetables, low in saturated fat, and consume adequate amounts of vitamin
D (>600 IU) and calcium (<1200 mg/d), with an energy deficit if weight loss is required
(Table 1) [28]. In this section, we review six studies in which healthy eating guidelines
and/or an energy deficit were implemented and the effect on FM and LM evaluated.
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Gilbert et al. [52] and Focht et al. [53] prescribed combined aerobic and resistance-
based exercise and conducted small group healthy eating seminars over a 12-week period
(Table 3). Gilbert et al. [52] reported a significant difference in LM but no change in FM
compared to usual care controls. However, the intervention group reduced their mean
Nutrients 2021, 13, 1664 10 of 18
FM from 34.5 to 31.6 kg compared to 30.4 to 29.0 kg in the control group. Although the
2.9 kg FM loss for the intervention group is potentially clinically meaningful, no within-
group changes were reported. Focht et al. [53] additionally included group-mediated
behaviour modification seminars based on social cognitive theory. Compared to usual
care controls, the intervention group significantly lost FM and BF%, with no change in LM.
Although the exercise and nutrition sessions were well adhered to, only a small subset
of the patients provided 3 day weighed food records and, therefore, overall nutritional
intake and compliance to nutrition advice were not confirmed. Further, 80% of patients
in the intervention group were overweight or obese and prescribed an energy deficit diet.
Therefore, the contribution of healthy eating guidelines versus an energy deficit diet to
promote FM and LM changes is unclear.
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O’Neill et al. [54] prescribed a 6-month home-based walking program, with a dietary
booklet encouraging healthy eating habits to patients of all cancer stages (T1–4), although
metastatic status was not reported (Table 3). The authors reported a significant reduction
in FM and BF%, with no change in LM when compared to usual care controls. While they
showed that a home-based intervention can reduce FM, body composition was measured
using the less precise technique of skinfold measurement. Similarly, to Focht et al. [53],
O’Neill et al. [54] encouraged an energy deficit diet only for patients who were overweight
or obese.
Freedland et al. [55] and Wilson et al. [57] targeted overweight or obese patients who
did not have symptomatic or bone metastases, respectively (Table 3). Freedland et al. [55]
prescribed home-based walking and a low carbohydrate diet over 6 months. Compared
to an 11% increase in FM for the usual care controls, the intervention group significantly
lost 16.2%. This substantial loss in FM has not been previously achieved in PCa patients on
ADT. However, the intervention group also had a significant decline in LM compared to
controls. A loss in LM is not uncommon while undergoing weight loss [46], with similar
patterns also noted by Baguley et al. [56] in their 12-week nutrition-only intervention
(Table 3). Wilson et al. [57] also demonstrated a significant reduction in FM but in contrast,
achieved LM preservation. Wilson et al. [57] included supervised resistance training and
protein supplementation, which are both considered important for LM preservation [59].
While the intervention designs are different, these studies provide preliminary evidence on
the potential for effective FM and LM management for obese ADT-treated PCa patients
through diet and exercise, which includes resistance training.
3.2. Protein Intake
The optimisation of protein intake is often incorporated into weight loss nutrition
plans to assist the body to mobilise fat and preserve muscle tissue by supporting the
upregulation of muscle protein synthesis [59]. Next, we describe a study examining protein
supplementation and resistance exercise.
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Dawson et al. [58] examined four groups of patients with PCa, including those with
metastatic disease (54.3%), over a 12-week period: exercise-only, exercise and protein
supplement, protein supplement-only, and usual care control (Table 3). No additional effect
was found for protein supplementation and as the study was not powered to detect changes
using a four-armed design, results were reported for exercise versus non-exercise groups.
In the exercise groups there was a significant increase in LM, ASM, and fat-free mass, a
significant reduction in BF%, with no changes in FM. The lack of a synergistic effect of
protein supplementation could be attributed to the low adherence of the protein-only group
who consumed 1.0 g/kg/day compared to 1.1–1.4 g/kg/dayin the other three groups.
Further, the protein supplements were given as 2 × 25 g daily doses. This may not have
been sufficient to stimulate muscle protein synthesis as each dose was equivalent to ~0.3 g
protein/kg body weight/day, compared to the ~0.4 g protein/kg body weight/daywhich
has been shown to be effective in increasing muscle protein synthesis when combined with
an acute bout of resistance exercise in ADT-treated PCa patients [59].
4. Discussion
The field of exercise oncology has rapidly developed over the last two decades and
we have presented 22 exercise and nutrition interventions conducted in ADT-treated PCa
patients between 2006 and 2020. Despite this growth in awareness of the benefits that
can be derived from undertaking these practices, most of the studies report only modest
changes in FM and LM. In this discussion, we summarise the key conclusions from these
studies and propose future research directions to progress the field.
The American Cancer Society weight loss guidelines for PCa patients are no different
to that of the general population (Table 1) [28]. Notably, Wilson et al. [57] was the only study
to incorporate these guidelines, which are recommended in clinical practice but have not
been verified in the ADT-treated population. Although these guidelines have the potential
to provide successful body composition changes, the metabolic changes induced by ADT
likely require different strategies to induce change compared to the non-ADT population,
as alluded to by the results of Alberga et al. [32], although the ADT and non-ADT cohorts
were not compared. In this regard, we provide an important initial platform to help identify
how these guidelines may be tailored to suit hypogonadal men. Potential questions that
would lead to further understanding of how to tailor these weight loss guidelines for
ADT-treated patients to maximise FM and LM changes are presented in Table 4.
With body composition changes occurring early in the treatment process [60], it would
be preferable to implement an exercise and nutrition intervention at initiation of ADT.
However, the magnitude of intervention-induced body composition changes could depend
on length of time on ADT, as demonstrated by Galvão et al. [15], where those initiating
ADT may experience small or no intervention-induced changes compared to those on
chronic ADT. Similarly, Hvid et al. [29] highlighted a patient on ADT for <6 months who
did not respond to the exercise intervention and gained 2.6 kg of FM accompanied by a loss
in LM of 5.0 kg. Ndjavera et al. [44] also reported no training effect on body composition
within the first 3 months of ADT. However, each of these studies were exercise only and
it has been established that manipulation of nutrition substantially decreases FM more
than exercise alone [61]. Therefore, those initiating ADT may only experience substantial
FM loss when nutrition is also addressed, as was demonstrated by Freedland et al. [55].
Regardless of the influence of length of time on ADT on body composition changes, exercise
and nutrition should still be recommended from therapy onset as there will be additional
health benefits and likely prevention of substantial FM and LM changes, as demonstrated
by Cormie et al. [41].
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Table 4. Potential questions for future research relating to the prescription of exercise and nutrition
for prostate cancer patients receiving ADT aiming to lose fat mass and gain lean mass.
Unanswered Questions for Prostate Cancer Patients on ADT
Aiming to Induce Fat Loss and Muscle Gain.
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Aerobic training
1. Will a low-i tensity lead-in period designed to build baseline
fitness reduce injury risk and improve adherence, particularly for
high-risk patients?
2. Is there a minimum intensity/volume for lipolysis and muscle
protein synthesis stimulation?
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questions that would lead to further understanding of how to tailor these weight loss 
guidelines for ADT-treated patients to maximise FM and LM changes are presented in 
Table 4. 
Table 4. Potential questions for future research relating t  the prescription of exercise and nutri-
tion for prostate cancer patients receiving ADT aiming to lose fat mass and gain lean mass. 
 Unanswered Questions for Prostate Cancer Patients on ADT 
Aiming to Induce Fat Loss and Muscle Gain. 
 
Aerobic training 
1. Will a low-intensity lead-in period designed to build 
baseline fitness reduce injury risk and improve adherence, 
particularly for high-risk patients? 
2. Is there a minimu  intensity/volume for lipolysis and 
muscle protei  synthesis stimulation? 
 
Resistance training 
1. Will a low-intensity familiarisation period designed to build 
baseline strength reduce injury risk and improve adherence, 
particularly for high-risk patients? 




1. Who is an energy deficit or healthy eating guideline diet 
most appropriate for? 
2. What is the optimum protein intake to enhance muscle 
protein synthesis leading to muscle gain? 
Other questions inclusive 
of all elements 
1. Are the benefits gained from a combined exercise and 
nutrition intervention influenced by length of time on ADT? 
2. What is a clinically significant change in fat and lean mass 
for prostate cancer patients on ADT? 
Images created with BioRender.com (accessed 5 April 2021). 
With body composition changes occurring early in the treatment process [60], it 
would be preferable to implement an exercise and nutrition intervention at initiation of 
ADT. However, the magnitude of intervention-induced body composition changes could 
depend on length of time on ADT, as demonstrated by Galvão et al. [15], where those 
initiating ADT may experience small or no intervention-induced changes compared to 
those on chronic ADT. Similarly, Hvid et al. [29] highlighted a patient on ADT for <6 
months who did not respond to the exercise intervention and gained 2.6 kg of FM accom-
panied by a loss in LM of 5.0 kg. Ndjavera et al. [44] also reported no training effect on 
body composition within the first 3 months of ADT. However, each of these studies were 
exercise only and it has been established that manipulation of nutrition substantially de-
creases FM more than exercise alone [61]. Therefore, those initiating ADT may only expe-
rience substantial FM loss when nutrition is also addressed, as was demonstrated by 
t iti l i t
1. Who is a energy deficit or healthy eating guideline diet most
appropriate for?
2. What is the optimum protein intake to enhance muscle protein
synthesis leading to muscle gain?
Other questions inclusive of
all el ments
1. Are the benefits gained from a combined exercise and nutrition
intervention influenced by length of time on ADT?
2. What is a clinically significant change in fat and lean mass for
r st t c c r ti ts ?
Images created with BioRend r.com (accessed on 5 April 2021).
Studies utilising a ulti-modal intervention compared to a single-exercise mode
showed m re consistent beneficial responses in both FM and LM. However, the majority of
the multi-modal s udies w re conducted by the s me research group [15,36,40,41,43,57] and,
therefore, may not represent th wider PCa population. Capitalising on the unique benefits
gained fr m utilising multiple exercise modes can induce concurrent desired adaptations of
FM and LM. However, there is uncertainty of best practice regar ing exercise prescription
to induce concurre t F loss and LM preserv tion or gain. While high-intensity [29,35,38]
and high-volume [54,55,57] exercise resulted in the greatest anges in FM or LM, they
may not initially be suitable for obes patients who have mul iple comorbidities without
undergoing a lead-in phase to improve baseline fitness. Moreover, the impact of such
interventions on patients with metastatic disease is unclear with only two studies actively
recruiting patients of this disease stage [35,58]. Further research is required into the benefits
of high-intensity or interval-based interventions, such as high-intensity interval training
or team/individual sports, for ADT-treated PCa patients. There may also be a minimum-
intensity threshold that stimulates lipolysis and muscle protein synthesis, as demonstrated
by Alberga et al. [32], where patients undertaking aerobic exercise continued to gain BF%
and lose LM. Furthermore, the use of multiple modes within the same session, as noted by
Newton et al. [36], may have an interference effect where physiological pathways involved
in manipulating body composition are not stimulated compared to when a single-exercise
mode is undertaken.
While bone measurements are not reported in the current review, it is important
to highlight that in addition to FM gain and LM loss patients receiving ADT may also
experience a loss of bone mass placing them at increased risk of osteopenia or osteoporo-
sis [5]. Newton et al. [36] assessed bone health as their primary outcome and reported
preliminary efficacy for the inclusion of impact training in a multi-modal intervention to
prevent ADT-induced bone loss. Patients at increased risk of bone loss may also benefit
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from increased calcium and vitamin D intake, which are included as part of the exercise
and nutrition guidelines for prostate cancer patients [28].
The number of interventions measuring body composition that encompassed a nutri-
tion component were less common than those investigating exercise. The employment of
an energy deficit was effective at reducing FM as shown in both the O’Neill et al. [54] and
Freedland et al. [55] studies. However, preventing LM loss when the body enters a catabolic
state requires further clarity. Protein optimisation and the inclusion of resistance training
may be important components to promote LM preservation or gain when undergoing
weight loss as suggested by Wilson et al. [57] and Dawson et al. [58]. However, as protein
supplementation is currently understudied in this population, it is not included in the PCa
weight loss guidelines and needs further evaluation. Continued research into optimal diet
and exercise prescriptions for prostate cancer patients may further improve the benefits
of weight loss and the potential impact on a patient’s prognosis with particular interest
in diet and exercise modes that influence microbiome activity. Differences in composition
of the gut microbiome have been reported in men with prostate cancer compared to men
with benign prostatic conditions and could contribute to prostate cancer pathogenesis and
progression [62].
As noted by Nilsen et al. [39], the definition of a clinically significant change in FM
and LM needs to be established. A 5% loss of body weight, which should be predominantly
FM loss [63], has been shown in the non-cancer population to improve blood pressure,
cholesterol, and insulin resistance [64]. While this percentage is also used for cancer
patients, the significance is unknown. For example, increases in trunk, visceral, and
intermuscular FM are associated with increased insulin resistance, a potential mechanism
for the observed association between FM and PCa progression [65,66]. Therefore, a loss of
FM in these regional areas, independent of whole-body FM loss, may be more beneficial
for PCa patients on ADT than a 5% loss in total body mass [29,63]. Further, it is unknown
whether a loss in FM will improve a PCa patient’s risk of disease progression, treatment-
related side effects, or comorbidity development. Both Santa Mina et al. [34] and Winters-
Stone et al. [42] demonstrated that weight or FM loss was associated with improvements
in biomarkers related to cancer progression, which has also been demonstrated in non-
ADT PCa patients [67]. Moreover, Galvão et al. [15] reported that a decrease in FM was
associated with decreased serum triglyceride levels. These studies provide preliminary
evidence that FM loss could improve patient outcomes.
5. Conclusions
Fat mass gain and LM loss are side effects of ADT that might be prevented or re-
versed with the implementation of an exercise and nutrition intervention. Patients on
ADT, particularly those who are obese, require effective strategies to improve their body
composition, which in turn may improve general health and cancer-free survival. The
implementation of such strategies will be most successful through the effective communi-
cation of a multi-disciplinary team including, but not limited to, oncologists, urologists,
dietitians, and exercise physiologists. The inclusion of a multi-modal exercise program is
needed to stimulate both lipolysis and muscle protein synthesis to ensure FM loss and LM
preservation. While exercise should be tailored to the preferences and fitness level of the
patient, when FM loss is the objective, energy expenditure should be maximised, which is
best achieved through higher volume and intensity with the inclusion of an energy deficit
diet. The optimal macronutrient composition of a diet for PCa patients on ADT is unclear
but should ultimately follow healthy eating guidelines and optimise protein intake.
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